Metagenomi Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Metagenomi Therapeutics, Inc. (MGX) reported Debt Securities, Available-for-sale, Unrealized Loss of $30.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2025-08-12
- Metagenomi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-06-30 was $4.00K, a 94.37% decline year-over-year.
- Metagenomi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-03-31 was $26.00K, a 91.13% decline year-over-year.
- Metagenomi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-12-31 was $41.00K.
- Metagenomi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-09-30 was -$362.00K.
- Metagenomi Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $110.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $30.00K 10-Q · filed 2025-08-12 | $71.00K derived: sum of 3 quarters · filed 2025-08-12 | -$291.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2025-03-31 | $26.00K 10-Q · filed 2025-05-13 | $67.00K derived: sum of 2 quarters · filed 2025-08-12 | -$295.00K derived: sum of 3 quarters · filed 2025-08-12 | -$224.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-12-31 | $41.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2025-08-12 | -$321.00K derived: sum of 2 quarters · filed 2025-08-12 | -$250.00K derived: sum of 3 quarters · filed 2025-08-12 | $43.00K 10-Q · filed 2025-08-12 | |
| 2024-09-30 | -$362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$291.00K derived: sum of 2 quarters · filed 2024-11-13 | $2.00K 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $364.00K 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $293.00K 10-Q · filed 2024-05-14 | ||||
| 2023-12-31 | $110.00K 10-Q · filed 2024-11-13 | $110.00K 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |